PfizerXSWX:PFE +0.68%66 5-Year Yield-on-Cost % is 3.91 as of Jul. 03, 2026, which is 13% below its 10-year median of 4.47. GuruFocus rates XSWX:PFE with a GF Score™ of 66/100 and a GF Value™ of CHF20.72 (Fairly Valued). The stock has 5 warning signs investors should review. Among 517 Drug Manufacturers companies, Pfizer ranks better than 84.33% on this metric.
Pfizer's yield on cost for the quarter that ended in Mar. 2026 was 3.91.
The historical rank and industry rank for Pfizer's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:PFE'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.95 Med: 4.47 Max: 8.72
Current: 3.91
During the past 13 years, Pfizer's highest Yield on Cost was 8.72. The lowest was 2.95. And the median was 4.47.
XSWX:PFE's 5-Year Yield-on-Cost % is ranked better than 84.33% of 517
companies
in the Drug Manufacturers industry
Industry Median: 2.34
vs XSWX:PFE: 3.91
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Pfizer 5-Year Yield-on-Cost % Related Terms
XSWX:PFE vs GILD, BMY, AMGN: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Pfizer's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pfizer's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Pfizer's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Pfizer is calculated as
Pfizer (XSWX:PFE) has a 5-Year Yield-on-Cost % of 3.91 as of Jul. 03, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pfizer and its competitors. This is 13% below median its historical median of 4.47. Over the past decade, Pfizer's 5-Year Yield-on-Cost % has ranged from 2.95 to 8.72. According to the industry distribution chart, Pfizer ranks #81 out of 517 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Pfizer's 5-Year Yield-on-Cost % too high?
Pfizer's current 5-Year Yield-on-Cost % of 3.91 is 13% below median its 10-year median of 4.47. Over the past 10 years, this metric has ranged from a low of 2.95 to a high of 8.72. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.34. Pfizer's value of 3.91 is 67.1% above this industry median. Based on the distribution chart, Pfizer ranks #81 out of 517 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pfizer has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's 5-Year Yield-on-Cost % compare to GILD and BMY?
According to the Drug Manufacturers industry distribution chart, Pfizer ranks #81 out of 517 companies for 5-Year Yield-on-Cost %. This places Pfizer in the top 16% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.34. Pfizer's value of 3.91 is 67.1% above this benchmark. Historically, Pfizer's own 5-Year Yield-on-Cost % has ranged from 2.95 to 8.72 over the past decade. While the company's 10-year median is 4.47 vs. the industry median of 2.34, Pfizer has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.34, based on 517 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pfizer's current 5-Year Yield-on-Cost % of 3.91 is 67.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pfizer and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pfizer's current 5-Year Yield-on-Cost % is 3.91, which is 13% below median its own 10-year median of 4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF20.72, compared to a current price of CHF19.48 — trading 6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 3.91, which is 13% below median its 10-year median of 4.47 and 67.1% above the Drug Manufacturers industry median of 2.34. Pfizer's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current 5-Year Yield-on-Cost % is 3.91 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (XSWX:PFE) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of CHF19.48 is trading 6% below its estimated GF Value™ of CHF20.72.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for XSWX:PFE:
5-Year Yield-on-Cost %: 3.91 (13% below median its 10-year median of 4.47)
GF Value™: CHF20.72 vs. price of CHF19.48 (6% below fair value)
Industry Position: 67.1% above the Drug Manufacturers median (#81 of 517)
No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
66GF Score
Get the complete analysis for XSWX:PFE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:PFE has been successfully added to your 